DGAP-News: MediClin AG / Key word(s): Final Results MEDICLIN grew significantly in 2017 - Management Board will propose the distribution of a dividend for the 2017 FY to the Annual General Meeting in May 23.03.2018 / 14:48 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- MEDICLIN grew significantly in 2017 - Management Board will propose the distribution of a dividend for the 2017 FY to the Annual General Meeting in May Offenburg, March 23, 2018 - The Management Board of MEDICLIN Aktiengesellschaft (MEDICLILN) was satisfied with the business development of the 2017 financial year at this year's press conference. "Consolidated sales and Group EBIT improved year-on-year despite higher expenses and the course has been set for further growth", said Jens Breuer, CFO of MEDICLIN. Significant increase in Group sales In the 2017 FY Group sales could be raised by EUR 28.7 mill. or 5.0 % up to EUR 609.1 mill. compared to the previous year. By that, consolidated sales were clearly above the 600 million euro mark at the first time. The Group-EBIT, adjusted for the one-off provision at the end of the year, improved from EUR 24.0 mill. to EUR 26.,7 mill. "MEDICLIN has reached its targets, both in terms of Group sales and Group EBIT in 2017", Jens Breuer commented on the development. MEDICLIN will continue to grow "We invested significantly more in 2017 than in previous years and we will do so in 2018 - about 40 million euro", said Volker Hippler, CEO of MEDICLIN and added: "We will expand selectively our capacities in high-growth areas and we will extend our service portfolio preferably cross-sector, as the current example shows in Lingen". MEDICLIN will invest about EUR 30 mill. in a new hospital building for Neurology, Neurological intensive care and Neurophysiology at the location Lingen. The project is funded by the state of Lower Saxony with about EUR 20 mill. "With this new building the MEDICLIN Hedon clinic will expand its existing service of neurological acute beds significantly. This will allow even more patients to benefit from the close connection to the rehabilitative neurological and traumatological medical department of the clinic", confirmed Ulf Ludwig, COO of MediClin, this positive development. Outlook For 2018 the Management Board forecasts sales growth of 5.0 % to 6.0 % and a Group EBIT in the range of EUR 26 mill. to EUR 28 mill. slightly above previous year's level. Dividend for the 2017 financial year In agreement with the Supervisory Board, the Management Board decided to propose to the Annual General Meeting on May 29, 2018, the payment of a dividend of 5 euro cents per share. Significant increase in number of employees In 2017, the average number of employees, calculated in full time employees, was 6,649 full-time employees, thus on average by 315 full-time-employees above previous year's average. MEDICLIN thus ensures the quality of treatment by well-trained staff and increasing personnel capacities Summary of the development of the Group and of the segments in 2017 FY MEDICLIN has achieved Group sales of EUR 609.1 mill. (previous year: EUR 580.3 mill.) in the 2017 financial year. Sales increase amounts to EUR 28.7 mill or 5.0 %. The adjusted Group-EBIT shows EUR 26.7 mill. (one-off provision for deptor warrant) and the adjusted total consolidated result EUR 20.9 mill. Without adjustment the Group-EBIT amounts to EUR 6.6 mill. (previous year: EUR 24.0 mill.) and the total consolidated result attributable to shareholders of MEDICLIN AG to EUR 3.9 mill. (previous year: 16.6 mill.). The earnings per share account to EUR 0.08 (previous year: EUR 0.35). In the post-acute segment, sales increased by EUR 22.2 mill. from EUR 351.0 mill. up to EUR 373.2 mill. Clinics that offer exclusively rehabilitation service as well as clinics that, in addition to their rehabilitation services, offer medical services in the acute neurology and acute psychosomatics in the scope of their integrated care concept contributed to this performance. The preliminary adjusted segment result amounts to EUR 20.8 mill. (previous year: EUR 18.5 mill.) In the acute segment, sales improved by EUR 6.0 milI. from EUR 210.6 mill. up to EUR 216.6 mill. Concerning the development in the segment it turns out that the measures taken are effective. In the 4th quarter 2017, both a significant sales increase against the first three quarters of 2017 as well as a positive segment-EBIT could be achieved, coming from a negative respectively break-even quarterly result. The preliminary segment-EBIT for the total year is EUR 2.3 mill. (previous year: EUR 5.8 mill.) In the nursing care business area sales increased from EUR 14.7 mill up to EUR 15.2 mill. Sound financial structure and stable results of operation The balance sheet and financial structures show that MEDICLIN is in a sound position. The equity ratio is 50.3 %, and the net financial debt amounts to EUR 20.6 mill. In addition to cash and cash equivalents of EUR 26,9 mill, the Group has sufficient credit lines to support capacity expansions in MEDICLIN's medical focus areas as well as to generate additional sales.. Hight investments secure growth In the 2017 financial year EUR 46.8 mill. (previous year: EUR 28.1 mill.) were invested in non-current assets (gross amount), including subsidies in the amount of EUR 7.2 mill. (previous year: EUR 6.4 mill.). EUR 17.6 mill. (previous year: EUR 18.5 mill.) was spent on maintenance and repair. The annual report 2017 will be available under www.mediclin.de in German and English. About MEDICLIN AG (Ticker: MED; WKN: 659 510) MEDICLIN owns 36 clinics, seven nursing care facilities, three home nursing care services and nine medical care centres. The Group has nearly 8,300 beds and a headcount of about 9,900. With its strong network, MEDICLIN can offer its patients integrated care from the first visit to the doctor to surgery, post-operative rehabilitation and follow-up care at home. Doctors, therapists and nurses work together closely to achieve the best results. MEDICLIN plans the care of persons in need in accordance with their individual requirements and personal needs, either at home or in a nursing care facility. MEDICLIN - A company of the Asklepios Group --------------------------------------------------------------------------- 23.03.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: MediClin AG Okenstraße 27 77652 Offenburg Germany Phone: +49 (0)781 488-326 Fax: +49 (0)781 488-184 E-mail: [email protected] Internet: www.mediclin.de ISIN: DE0006595101 WKN: 659510 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange End of News DGAP News Service --------------------------------------------------------------------------- 668169 23.03.2018